Identification of pyrazolopyridazinones as PDEδ inhibitors

Nature Communications

Volumn 7, Issue , 2016, Pages

  Papke, Björn ^a   Murarka, Sandip ^a   Vogel, Holger A ^a   Martín Gago, Pablo ^a   Kovacevic, Marija ^a   Truxius, Dina C ^a   Fansa, Eyad K ^a   Ismail, Shehab ^a,b   Zimmermann, Gunther ^a   Heinelt, Kaatje ^a   Schultz Fademrecht, Carsten ^c   Al Saabi, Alaa ^c   Baumann, Matthias ^c   Nussbaumer, Peter ^c   Wittinghofer, Alfred ^a   Waldmann, Herbert ^a,d   Bastiaens, Philippe I H ^a,d  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c Lead Discovery Center GmbH   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DELTARASIN; DELTAZINONE 1; PHOSPHODIESTERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; MOLECULAR LIBRARY; PHOSPHODIESTERASE VI; PROTEIN BINDING; PROTEIN P21; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; RECOMBINANT PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; MEMBRANE; PHENOTYPE; PLASMA; PROTEIN; TOXICITY;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; PANCREATIC CANCER CELL LINE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; PANCREATIC DUCT; PATHOLOGY; PHARMACOLOGY; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BINDING SITES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 6; EPITHELIAL CELLS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR DOCKING SIMULATION; PANCREATIC DUCTS; PHOSPHODIESTERASE INHIBITORS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS P21(RAS); PYRAZINES; PYRAZOLES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84964794121     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11360     Document Type: Article

References (23)

1. Wittinghofer, A. Signal transduction via Ras. Biol. Chem. 379, 933-937 (1998).
2. Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517-531 (2008).
3. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774 (2011).
4. Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828-851 (2014).
5. Schmick, M., Kraemer, A. & Bastiaens, P. I. Ras moves to stay in place. Trends Cell Biol. 25, 190-197 (2015).
6. Hancock, J. F., Paterson, H. & Marshall, C. J. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63, 133-139 (1990).
7. Schmick, M. et al. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 157, 459-471 (2014).
8. Chandra, A. et al. The GDI-like solubilizing factor PDEdelta sustains the spatial organization and signalling of Ras family proteins. Nat. Cell Biol. 14, 148-158 (2012).
9. Hanzal-Bayer, M., Renault, L., Roversi, P., Wittinghofer, A. & Hillig, R. C. The complex of Arl2-GTP and PDE delta: from structure to function. EMBO J. 21, 2095-2106 (2002).
10. Zhang, H., Constantine, R., Frederick, J. M. & Baehr, W. The prenyl-binding protein PrBP/delta: a chaperone participating in intracellular trafficking. Vision Res. 75, 19-25 (2012).
11. Nancy, V., Callebaut, I., El Marjou, A. & de Gunzburg, J. The delta subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases. J. Biol. Chem. 277, 15076-15084 (2002).
12. Ismail, S. A. et al. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nat. Chem. Biol. 7, 942-949 (2011).
13. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
14. Young, A. et al. Ras signaling and therapies. Adv. Cancer Res. 102, 1-17 (2009).
15. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003).
16. Montagut, C. & Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283, 125-134 (2009).
17. Bivona, T. G. et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 21, 481-493 (2006).
18. Singh, A. et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500 (2009).
19. Babij, C. et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 71, 5818-5826 (2011).
20. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945 (2004).
21. Ruvinsky, I. et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Gene Dev. 19, 2199-2211 (2005).
22. Chidley, C., Haruki, H., Pedersen, M. G., Muller, E. & Johnsson, K. A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. Nat. Chem. Biol. 7, 375-383 (2011).
23. Grecco, H. E., Roda-Navarro, P. & Verveer, P. J. Global analysis of time correlated single photon counting FRET-FLIM data. Opt. Express 17, 6493-6508 (2009).